Shearman & Sterling advised the underwriters of Mineralys Therapeutics, Inc.’s upsized initial public offering of 13,800,000 shares of common stock at a public offering price of $16.00 per share, resulting in gross proceeds to the Company of $220.8 million, before deducting underwriting discounts and commissions and offering expenses. The 13,800,000 shares included 1,800,000 of shares issued pursuant to the underwriters’ option to purchase additional shares. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “MLYS” on February 10, 2023.

BofA Securities, Evercore ISI, Stifel, Guggenheim Securities, Credit Suisse and Wells Fargo Securities acted as joint book-running managers for the offering.

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone.

The Team